L-Canavanine sulfateCAS# 2219-31-0 |
- BMS-708163 (Avagacestat)
Catalog No.:BCC2104
CAS No.:1146699-66-2
- DAPT (GSI-IX)
Catalog No.:BCC3618
CAS No.:208255-80-5
- YO-01027 (Dibenzazepine, DBZ)
Catalog No.:BCC2100
CAS No.:209984-56-5
- Semagacestat (LY450139)
Catalog No.:BCC3610
CAS No.:425386-60-3
- Flurizan
Catalog No.:BCC2342
CAS No.:51543-40-9
- E 2012
Catalog No.:BCC1540
CAS No.:870843-42-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2219-31-0 | SDF | Download SDF |
PubChem ID | 275 | Appearance | Powder |
Formula | C5H12N4O3 | M.Wt | 176.2 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | H2O : 100 mg/mL (364.63 mM; Need ultrasonic and warming) | ||
Chemical Name | 2-amino-4-(diaminomethylideneamino)oxybutanoic acid | ||
SMILES | C(CON=C(N)N)C(C(=O)O)N | ||
Standard InChIKey | FSBIGDSBMBYOPN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | NO synthase inhibitor. |
L-Canavanine sulfate Dilution Calculator
L-Canavanine sulfate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.6754 mL | 28.3768 mL | 56.7537 mL | 113.5074 mL | 141.8842 mL |
5 mM | 1.1351 mL | 5.6754 mL | 11.3507 mL | 22.7015 mL | 28.3768 mL |
10 mM | 0.5675 mL | 2.8377 mL | 5.6754 mL | 11.3507 mL | 14.1884 mL |
50 mM | 0.1135 mL | 0.5675 mL | 1.1351 mL | 2.2701 mL | 2.8377 mL |
100 mM | 0.0568 mL | 0.2838 mL | 0.5675 mL | 1.1351 mL | 1.4188 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Macrocarpal N
Catalog No.:BCN5811
CAS No.:221899-21-4
- Zotarolimus(ABT-578)
Catalog No.:BCC5481
CAS No.:221877-54-9
- Methylswertianin
Catalog No.:BCN8505
CAS No.:22172-17-4
- Conocarpan
Catalog No.:BCN5053
CAS No.:221666-27-9
- OBAA
Catalog No.:BCC6716
CAS No.:221632-26-4
- L-Menthol
Catalog No.:BCN4971
CAS No.:2216-51-5
- Boron tributoxide
Catalog No.:BCN8281
CAS No.:688-74-4
- 2,6-Dimethoxy-1-acetonylquinol
Catalog No.:BCN5052
CAS No.:2215-96-5
- 1-Benzyl-1H-indazol-3-ol
Catalog No.:BCC8458
CAS No.:2215-63-6
- Stigmastane-3,6-dione
Catalog No.:BCN5051
CAS No.:22149-69-5
- Hopane-3beta,22-diol
Catalog No.:BCN4852
CAS No.:22149-65-1
- Kaempferol 3-gentiobioside
Catalog No.:BCN3345
CAS No.:22149-35-5
- Lyn peptide inhibitor
Catalog No.:BCC5895
CAS No.:222018-18-0
- Pyrantel Pamoate
Catalog No.:BCC4958
CAS No.:22204-24-6
- Naproxen
Catalog No.:BCC9091
CAS No.:22204-53-1
- Dihydroseselin
Catalog No.:BCN8258
CAS No.:2221-66-1
- Dehydroglaucine
Catalog No.:BCN2548
CAS No.:22212-26-6
- Cucurbitacin I
Catalog No.:BCC2439
CAS No.:2222-07-3
- Thalrugosaminine
Catalog No.:BCN7745
CAS No.:22226-73-9
- Fern-7-en-19-one
Catalog No.:BCN6443
CAS No.:222294-61-3
- 7-Amino-3-methyl-3-cephem-4-carboxylic acid
Catalog No.:BCC8776
CAS No.:22252-43-3
- Ipratropium Bromide
Catalog No.:BCC3795
CAS No.:22254-24-6
- Methyl 6-hydroxyangolensate
Catalog No.:BCN5054
CAS No.:22255-07-8
- alpha-Amyrin palmitate
Catalog No.:BCN5055
CAS No.:22255-10-3
Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid.[Pubmed:7071589]
Science. 1982 Apr 23;216(4544):415-7.
Hematologic and serologic abnormalities similar to those observed in human systemic lupus erythematosus (SLE) developed in cynomolgus macaques fed alfalfa sprouts. L-Canavanine sulfate, a constituent of alfalfa sprouts, was incorporated into the diet and reactivated the syndrome in monkeys in which an SLE-like syndrome had previously been induced by the ingestion of alfalfa seeds or sprouts.
Selective inhibitors of neuronal nitric oxide synthase--is no NOS really good NOS for the nervous system?[Pubmed:9226999]
Trends Pharmacol Sci. 1997 Jun;18(6):204-11.
It is now ten years since NO was shown to account for the biological activity of endothelium-derived relaxing factor (EDRF). It is also the tenth anniversary of the identification of L-NG monomethyl arginine (L-NMMA) as the very first inhibitor of NO biosynthesis. That EDRF and NO were one and the same sparked an explosion of interest in the biochemistry and pharmacology of NO which has yet to subside. In contrast, the first ever nitric oxide synthase (NOS) inhibitor slipped seamlessly into the literature virtually without comment at the time. Over the following decade, L-NMMA (and like NOS inhibitors) have proved invaluable as tools for probing the biological roles of NO in health and disease and, in particular, have increased our understanding of the function of NO in the nervous system. Further advances in this important area now require the development of inhibitors selective for the neuronal isoform of NOS (nNOS). Here, Philip Moore and Rachel Handy provide an up-to-date account of the literature regarding the biochemical and pharmacological characterization of NOS inhibitors with particular reference to compounds with greater selectivity for the nNOS isoform.
Facilitatory effects of somatostatin on reduced uptake of 2-deoxyglucose in cerebral cortical and hippocampal slices from aged rats.[Pubmed:7851504]
Eur J Pharmacol. 1994 Oct 14;269(2):269-72.
The aim of the present study was to determine whether or not the reduction of 2-deoxyglucose uptake by the cerebral cortical slices in aged rats (22-23 months old) was attenuated by somatostatin or carbachol. In 8-week-old rats, somatostatin and carbachol produced concentration-dependent increases in 2-deoxyglucose uptake. 2-Deoxyglucose uptake of the cortical slices in 22-23-month-old rats was significantly facilitated by treatment with 0.1-1 microM somatostatin or 1-100 microM carbachol. Metabolic responses to somatostatin or carbachol were quite similar in young and aged rats. The present results demonstrated that 2-deoxyglucose uptake by the cerebral cortex was facilitated by somatostatin and carbachol in both young and old rats.
L-canavanine restores blood pressure in a rat model of endotoxic shock.[Pubmed:7535234]
Eur J Pharmacol. 1994 Dec 12;271(1):87-92.
Administration of lipopolysaccharide to anaesthetised rats produced a reduction in mean arterial pressure, an increase in heart rate, and death at 4-6 h. Intravenous infusion of NG-nitro-L-arginine methyl ester (50 mg/kg), an inhibitor of constitutive and inducible nitric oxide (NO) synthase, 60 min after challenge with lipopolysaccharide, caused an immediate increase in blood pressure followed by a precipitous fall in pressure, and death. In contrast, intravenous infusion of L-canavanine (100 mg/kg), reported to be a selective inhibitor of inducible NO synthase in vitro, 60 min and 180 min after lipopolysaccharide challenge, produced an increase in mean arterial pressure and reversed the lipopolysaccharide induced hypotension. However, in lipopolysaccharide challenged animals protected from hypotension by administration of L-canavanine (60 min post challenge), intravenous infusion of NG-nitro-L-arginine methyl ester at 180 min post challenge caused an immediate rise in mean arterial pressure, followed by a rapid fall in blood pressure and heart rate, and sudden death. In contrast, a second dose of L-canavanine at 180 min post challenge maintained blood pressure for the duration of the experiment. These findings indicate that inhibition of both constitutive and inducible NO synthase during endotoxaemia is lethal. However, the use of a selective inhibitor of inducible NO synthase restores mean arterial pressure to baseline, and offers a therapeutic approach to managing hypotension in shock.